Who Supplies Bisoprolol to India from JAPAN

To import finished pharmaceutical formulations containing Bisoprolol into India, the foreign manufacturer must obtain a Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This involves submitting an application to the Drugs Controller General of India (DCGI) along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes several months, depending on the completeness of the application and the need for any additional information.

An Import License is also required, which can be obtained by submitting an application to the Directorate General of Foreign Trade (DGFT). This license is valid for three years and must be renewed before expiration.

For Bisoprolol formulations under HS Code 30049079, the manufacturer must provide evidence of compliance with Indian pharmacopoeia standards and demonstrate the safety and efficacy of the product.

Imported pharmaceutical formulations containing Bisoprolol must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product stability in India's climate.

Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity of the CoA and assess the quality of the product. If a batch fails inspection, it may be rejected, leading to potential financial losses and reputational damage for the importer.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, including enhanced scrutiny of stability data and GMP compliance. The Production Linked Incentive (PLI) scheme introduced in 2024 aims to boost domestic manufacturing, potentially affecting the volume of finished formulation imports.

Bilateral agreements between India and Japan have facilitated smoother trade processes, including mutual recognition of GMP certifications, which may expedite import procedures for Japanese manufacturers.

India imports finished Bisoprolol formulations primarily due to the demand for branded products, specific dosage forms, and formulations not produced domestically. The market size for Bisoprolol formulations in India is substantial, with a growing number of patients requiring hypertension treatment.

Domestic manufacturers may lack the capacity to produce certain specialized formulations, leading to reliance on imports to meet market needs.

The Basic Customs Duty (BCD) for Bisoprolol formulations under HS Code 30049079 is 10%.

The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty.

Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, calculated on the total of the CIF value plus customs duties.

There are no specific exemptions or concessional duties for products originating from Japan under this HS Code.

India sources Bisoprolol formulations from Japan due to the high quality, advanced manufacturing technologies, and adherence to international standards. Japanese manufacturers often hold patents for specific formulations and dosage forms, providing a competitive edge.

Other suppliers include China, Germany, and the United States. However, Japan's reputation for quality and innovation makes it a preferred source for certain specialized formulations.

India imports Bisoprolol formulations from Japan due to the high quality, advanced manufacturing technologies, and adherence to international standards. Japanese manufacturers often hold patents for specific formulations and dosage forms, providing a competitive edge.

Other suppliers include China, Germany, and the United States. However, Japan's reputation for quality and innovation makes it a preferred source for certain specialized formulations.

Compared to China, the European Union, and the United States, Japan offers superior quality, advanced manufacturing technologies, and adherence to international standards. Japanese manufacturers often hold patents for specific formulations and dosage forms, providing a competitive edge.

While other countries may offer lower prices, Japan's reputation for quality and innovation makes it a preferred source for certain specialized formulations.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions.

Past shortages have occurred due to global supply chain disruptions, highlighting the need for strategic sourcing and risk management.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate single-source risk.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) or Documents Against Payment (DA/DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain from the Directorate General of Foreign Trade.
2. 2CDSCO Registration Certificate: Apply under Form 41 for the manufacturing premises.
3. 3Drug Import License: Obtain under Form 10 for the specific product.
4. 4No Objection Certificate (NOC): From the product license holder, if applicable.
5. 5Customs Broker: Engage a licensed Customs House Agent for clearance.
6. 6Advance Ruling: Seek for HS Code 30049079 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP): Issued by the